Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Men and women ≥18 years of age
Eastern Cooperative Oncology Group Performance Status of 0 or 1
Untreated and histologically confirmed unresectable Stage III or Stage IV melanoma, as per the staging system of the American Joint Committee on Cancer
Measurable disease as per Response Evaluation Criteria in Solid Tumors 1.1
Tumor tissue from an unresectable or metastatic site of disease must be provided for biomarker analyses
Known BRAF wild-type, as per regionally acceptable V600 mutational status testing. BRAF mutant patients and those with indeterminate or unknown BRAF status are not permitted to randomize
You may not be if
Active brain metastases or leptomeningeal metastases
Ocular melanoma
Any active, known, or suspected autoimmune disease
Clareo Health | Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma
